Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

428
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
428
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

342
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
342
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

331
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
331
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

555
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
555

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conservative management of duodenal haematoma in a patient with severe haemophilia: A case report and literature review.

Haemophilia : the official journal of the World Federation of Hemophilia·2020
Same author

Impact of obesity on the risk of venous thromboembolism in an inpatient pediatric population.

Pediatric hematology and oncology·2014
See all related articles

Related Experiment Video

Updated: Mar 5, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K

Anticoagulation Therapy in Children.

Vlad Calin Radulescu1

  • 1Department of Pediatric Hematology Oncology, University of Kentucky, Lexington, Kentucky.

Seminars in Thrombosis and Hemostasis
|March 28, 2017
PubMed
Summary

Pediatric venous thromboembolism (VTE) management is largely based on adult data, despite developmental differences. New oral anticoagulants show promise, with ongoing trials poised to refine pediatric thrombosis treatment.

Area of Science:

  • Pediatric Hematology
  • Thrombosis and Hemostasis
  • Pharmacology

Background:

  • Venous thromboembolism (VTE) is rare in children but increasing.
  • Pediatric VTE management often extrapolates from adult data.
  • Children's unique physiology impacts anticoagulant effectiveness.

Purpose of the Study:

  • To review current pediatric VTE management strategies.
  • To highlight limitations of adult-based approaches in children.
  • To discuss the potential of novel oral anticoagulants in pediatric thrombosis.

Main Methods:

  • Literature review of pediatric VTE management.
  • Analysis of pharmacokinetic and pharmacodynamic data in children.
  • Overview of ongoing clinical trials for novel oral anticoagulants.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

9.0K

Related Experiment Videos

Last Updated: Mar 5, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

9.0K

Main Results:

  • Heparins and vitamin K antagonists remain primary pediatric anticoagulants.
  • Limited pediatric data exists for direct thrombin inhibitors.
  • Novel oral anticoagulants demonstrate potential advantages but require more pediatric evidence.

Conclusions:

  • Current pediatric VTE treatment is suboptimal due to limited pediatric-specific data.
  • Novel oral anticoagulants (NOACs) are a promising area for future pediatric thrombosis care.
  • Ongoing clinical trials are crucial for establishing safe and effective NOAC use in children.